Literature DB >> 8806790

Effector mechanism of experimental autoimmune sialadenitis in the mouse model for primary Sjögren's syndrome.

Y Hayashi1, N Haneji, H Hamano, K Yanagi, M Takahashi, N Ishimaru.   

Abstract

We have recently established a new animal model for primary Sjögren's syndrome in NFS/sld mutant mice thymectomized 3 days after birth (3dTX) bearing an autosomal recessive gene with sublingual gland differentiation arrest. In this study, we analyze developing mechanisms of experimental autoimmune sialadenitis (EAS) in the mouse model, focusing on local expressions of cytokine and cell adhesion molecule genes by reverse transcriptase-polymeric chain reaction (RT-PCR) and immunohistochemistry, kinetic analysis of splenic lymphocytes expressing activation markers, and I-Aq class-II molecules by flow cytometry (FACS). We found up-regulation of local cytokine genes (IL-1 beta, TNF-alpha, IL-2, IFN-gamma, IL-6, IL-10, IL-12p40) and cell adhesion molecule genes (ICAM-1, LFA-1, CD44, Mel-14) in the salivary glands from mice with EAS by RT-PCR, which were supported by immunohistochemistry. FACS analysis demonstrated that a significant proportion of splenic CD4+ T cells express activation markers (CD44, LFA-1, Mel-14low, CD45RB(low)) at a high level and an increase in expression of B220+ B cells bearing I-Aq class-II molecules. These data suggest that spontaneous EAS in 3dTX NFS/sld mutant mice may be triggered by an in situ activation of autoreactive CD4+ T cells comprising unique cytokine profile (high levels of IL-2, IFN-gamma, IL-10, and IL-12p40 mRNA) in the salivary glands.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806790     DOI: 10.1006/cimm.1996.0196

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  8 in total

Review 1.  Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome.

Authors:  M R Kok; B J Baum; P P Tak; S R Pillemer
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

2.  Treatment with anti-CD86 costimulatory molecule prevents the autoimmune lesions in murine Sjögren's syndrome (SS) through up-regulated Th2 response.

Authors:  K Saegusa; N Ishimaru; K Yanagi; N Haneji; M Nishino; M Azuma; I Saito; Y Hayashi
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

Review 3.  The value of animal models to study immunopathology of primary human Sjögren's syndrome symptoms.

Authors:  Amy Donate; Alexandria Voigt; Cuong Q Nguyen
Journal:  Expert Rev Clin Immunol       Date:  2014-02-10       Impact factor: 4.473

Review 4.  Studying Sjögren's syndrome in mice: What is the best available model?

Authors:  Ghada Abughanam; Ola M Maria; Simon D Tran
Journal:  J Oral Biol Craniofac Res       Date:  2020-12-08

Review 5.  Mouse Models of Primary Sjogren's Syndrome.

Authors:  Young-Seok Park; Adrienne E Gauna; Seunghee Cha
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

6.  Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity.

Authors:  Kaoru Saegusa; Naozumi Ishimaru; Kumiko Yanagi; Rieko Arakaki; Kouichi Ogawa; Ichiro Saito; Nobuhiko Katunuma; Yoshio Hayashi
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

7.  Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren's syndrome.

Authors:  Gil-Jin Shim; Margaret Warner; Hyun-Jin Kim; Sandra Andersson; Lining Liu; Jenny Ekman; Otabek Imamov; Margaret E Jones; Evan R Simpson; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-16       Impact factor: 11.205

Review 8.  Sjögren's syndrome: studying the disease in mice.

Authors:  Nicolas Delaleu; Cuong Q Nguyen; Ammon B Peck; Roland Jonsson
Journal:  Arthritis Res Ther       Date:  2011-06-13       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.